유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - инсулин аспарт - Захарен диабет - Лекарства, използвани при диабет - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

baxter holding b.v. - insulin human (rdna) - Захарен диабет - Лекарства, използвани при диабет - inpremzia is indicated for the treatment of diabetes mellitus.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - Множествена Склероза, Рецидивно-Ремиттирующее - Имуносупресори - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - Множествена Склероза, Рецидивно-Ремиттирующее - Иммунодепрессанты селективен иммунодепрессанты - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Антинеопластични средства - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - Лимфом, мантел-клетка - Инхибитори на протеинкиназы - treatment of mantle cell lymphoma (mcl).

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - инсулин глулизин - Захарен диабет - Лекарства, използвани при диабет - Лечение на възрастни, юноши и деца, шест и повече години с диабет, където се изисква лечение с инсулин.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

astrazeneca ab - екзенатид - Захарен диабет тип 2 - Лекарства, използвани при диабет - bydureon, се посочва в възрастни от 18 години и по-възрастни с диабет тип 2, за подобряване на контрол доведе до бъбречна недостатъчност в комбинация с други глюкоза, намаляване на лекарствени продукти при терапия при използване заедно с диета и физически упражнения не осигурява адекватен контрол доведе до бъбречна недостатъчност (виж раздел 4. 4, 4. 5 и 5. 1 за наличните данни за различни комбинации). bydureon е показан при лечение на захарен диабет тип 2 в комбинация с:metforminsulphonylureathiazolidinedionemetformin и sulphonylureametformin и thiazolidinedionein възрастни, които не са достигнали до адекватен гликемичен контрол на максимално переносимой дози от тези устни терапии.